(News Bulletin 247) – Bank of America reiterated its buy recommendation on Merck stock on Monday, seeing a favorable strategic development in the announcement of the acquisition of Prometheus.
From the broker’s point of view, this is a new step in the right direction in order to limit the risk of excessive dependence on Keytruda, the cancer drug star of the American pharmaceutical group.
According to BofA, Prometheus’ lead candidate, PRA023, could be a potential ‘disruptor’ in the field of inflammation and immunology, given its many potential applications.
According to the broker, which is considering the possibility of marketing by 2026, the molecule could exceed five billion dollars in annual sales by 2030.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
